Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

被引：0
|
作者：
David Schnell
Susanne Buschke
Holger Fuchs
Dietmar Gansser
Rainer-Georg Goeldner
Martina Uttenreuther-Fischer
Peter Stopfer
Sven Wind
Marc Petersen-Sylla
Atef Halabi
Rüdiger Koenen
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG,Translational Medicine and Clinical Pharmacology
[2] Boehringer Ingelheim Pharma GmbH & Co KG,Drug Metabolism and Pharmacokinetics
[3] Boehringer Ingelheim Pharma GmbH & Co KG,Global Biometrics and Clinical Applications
[4] Boehringer Ingelheim Pharma GmbH & Co KG,Clinical Development and Medical Affairs
[5] Kiel GmbH,Clinical Research Services (CRS)
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 74卷
关键词：
Afatinib; Hepatic impairment; Pharmacokinetics; Human; Epidermal growth factor receptor (EGFR); Tyrosine kinase inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：267 / 275
页数：8
相关论文
共 50 条
  • [21] Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
    Akifumi Kurata
    Takafumi Yoshida
    Megumi Inoue
    Tomoko Ishizuka
    Takafumi Nakatsu
    Takako Shimizu
    Manabu Kato
    Yasuhiro Nishikawa
    Hitoshi Ishizuka
    [J]. Advances in Therapy, 2020, 37 : 253 - 264
  • [22] Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment
    Marcinak, John
    Vakilynejad, Majid
    Kogame, Akifumi
    Tagawa, Yoshihiko
    [J]. DRUGS IN R&D, 2018, 18 (02) : 109 - 118
  • [23] Pharmacokinetics of benapenem for injection in subjects with mild to moderate renal impairment
    Haijing Yang
    Min Zhang
    Yuancheng Chen
    Hong Ren
    Hong Zhang
    Chen Yu
    Jianda Lu
    Li You
    Jicheng Yu
    Hong Liang
    Cuilan Xiao
    Zishuang He
    Jufang Wu
    Jun Xue
    Jing Zhang
    [J]. European Journal of Clinical Pharmacology, 2022, 78 : 1079 - 1086
  • [24] Pharmacokinetics of benapenem for injection in subjects with mild to moderate renal impairment
    Yang, Haijing
    Zhang, Min
    Chen, Yuancheng
    Ren, Hong
    Zhang, Hong
    Yu, Chen
    Lu, Jianda
    You, Li
    Yu, Jicheng
    Liang, Hong
    Xiao, Cuilan
    He, Zishuang
    Wu, Jufang
    Xue, Jun
    Zhang, Jing
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (07) : 1079 - 1086
  • [25] THE EFFECT OF MILD TO MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF ALISPORIVIR (ALV)
    Kovacs, S. J.
    Ke, J.
    Praestgaard, J.
    Barve, A.
    Zhang, J.
    Maietta, R.
    Sunkara, G.
    Stein, D. S.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S345 - S345
  • [26] Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics and Safety of Carisbamate
    Moore, Kenneth
    Zannikos, Peter
    Solanki, Bhavna
    Greenspan, Andrew
    Verhaeghe, Tom
    Brashear, H. Robert
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (05): : 738 - 746
  • [27] FTY720 pharmacokinetics in mild to moderate hepatic impairment
    Kovarik, JM
    Schmouder, RL
    Wang, SY
    Wiegand, H
    Dilzer, SC
    Lasseter, KC
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (04): : 446 - 452
  • [28] PHARMACOKINETICS OF TMC435 IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT
    Sekar, V.
    Simion, A.
    Peeters, M.
    Spittaels, K.
    Lawitz, E.
    Marbury, T. C.
    De Smedt, G.
    [J]. JOURNAL OF HEPATOLOGY, 2011, 54 : S193 - S193
  • [29] The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (08): : 944 - 952
  • [30] PHARMACOKINETICS (PK) OF THE PAN-HER INHIBITOR DACOMITINIB (D) IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT
    O'Connell, J.
    Plotka, A.
    Liang, Y.
    Boutros, T.
    Ni, G.
    Masters, J.
    DeMicco, M.
    Pardo, P.
    Bello, C.
    Giri, N.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 : 83 - 83
12345